INTRODUCTION {#sec1-1}
============

Rheumatoid arthritis (RA) is one of the most common inflammatory rheumatic disease in which joints of the hand and feet are mainly affected ([@ref1]). One of the main features in the pathophysiology of this disease is the production of inflammatory cytokines in the synovial membrane and the subsequent joint damage.

Leptin is a cytokine that mediates both immune cell recruitment and complex intracellular signaling control mechanisms that characterize inflammation, thus it may have a potential role in RA. Several studies have reported a two to three times elevation in serum leptin levels in women as compared to men ([@ref2],[@ref3]), furthermore, serum leptin levels are high in RA patients as compared to controls ([@ref4]). Leptin levels also correlate with disease activity ([@ref5],[@ref9]) and proinflammatory activity ([@ref12]).

In 1994, it was discovered that leptin is produced by adipocytes and is crucial for the control of appetite ([@ref13]). This hormone exhibits a structural similarity with the Granulocyte Colony-Stimulating Factor (G-CSF) and with a number of cytokines including Interleukin 6 (IL-6), Ciliary Neurotrophic Factor (CNTF) and Leukemia Inhibitory Factor (LIF) ([@ref14],[@ref15]).

In humans, blood leptin levels are proportional to the amount of body fat ([@ref16]). At the level of the Central Nervous System (CNS) leptin controls energy expenditure ([@ref17]), whereas in the periphery it regulates endocrinal function, reproduction, and immunity ([@ref18]).

Leptin acts by binding to specific receptors present on cell membranes. This receptor is expressed in many tissues in multiple isoforms, resulting from a "splicing" of its alternate mRNA.

The different isoforms of the receptor can be classified as long (OB-Rb), short (OB-Ra, OB-Rc, and OB-Rd) and soluble (OB-Re) ([@ref19]). Considering the multiple isoforms, it is possible to hypothesize the possibility that leptin exerts multiple effects on tissues.

Several single nucleotide polymorphisms and mutations of leptin receptor *(LEPR)* gene have been linked to diseases accompanying obesity and/or obesity-related diseases in different populations ([@ref20]), nonetheless there are very few studies evaluating their association with RA.

As far, three missense variants Q223R, K109R, K656N in the *LEPR* gene have been described, and their associations with adiposity examined. In most cases, the *LEPR* Q223R polymorphism has been associated with high serum leptin levels; this variant is a substitution of G\>A at 668 position, a putative leptin binding region ([@ref20],[@ref21]).

The aim of the present study was to evaluate the possible association between the Q223R *LEPR* polymorphism and leptin levels in patients with RA from Western Mexico.

MATERIALS AND METHODS {#sec1-2}
=====================

A cross-sectional study was performed with a Mexican mestizo population of 70 RA patients and 74 Control subjects (CS) from Guadalajara, State of Jalisco, Mexico. The diagnosis of RA was based on the American College of Rheumatology criteria and the patients were selected from an outpatient rheumatology clinic from the public healthcare system. The CS were randomly selected from an open population sample. The study was approved by the Investigation, Ethics and Biosecurity Committee of the Health Sciences University Center of the University of Guadalajara. All participants gave informed consent prior to inclusion in the study; the study was carried out in accordance with the principles of the World Medical Association's Declaration of Helsinki.

Following blood sampling, serum leptin levels were determined, DNA was extracted and *LEPR* genotypes were identified. Additionally, a detailed clinical history was collected from each participant.

Leptin levels were quantified using a solid phase enzyme-linked immunosorbent assay (ELISA) (DRG International, Inc., USA). The erythrocyte sedimentation rate (ESR) was determined using the Westergren method. The C-reactive protein (CRP) and rheumatoid factor (RF) were quantified using Immage™ Immunochemistry system (Beckman Coulter System).

The Miller method was used to extract DNA. The DNA pellet was resuspended in 200 µL of sterile water, and concentration and integrity were calculated by spectrophotometry. The Q223R variants of the *LEPR* gene were determined by PCR-RFLP technique, as described previously ([@ref25]).

Descriptive statistics (mean and standard deviation or median and percentile 5-95) were used to describe participant characteristics, additional statistical analysis was performed following data normality check by the Kolmogorov-Smirnov test.

Chi-square test was used to evaluate the statistical association of the polymorphism. Odds Ratio (OR) was calculated for the evaluation of polymorphism as a risk factor associated with rheumatoid arthritis.

The Student *t* or Mann-Whitney test was used to evaluate mean or median differences between the two study groups. One-way ANOVA with Bonferroni *post-hoc* tests were used to evaluate the mean differences between the genotypes of the *LEPR* gene.

Pearson or Spearman correlations were used to evaluate the correlation between leptin levels with age, weight, height, Body Mass Index (BMI), CRP, RF, DAS28 and disease duration. Statistical significance was reported when p values were below 0.05. Data analysis was carried out with the SPSS version 19.0 statistical package (SPSS, Inc., Chicago, IL).

RESULTS {#sec1-3}
=======

The clinical characteristics of the study subjects are shown in [Table 1](#table001){ref-type="table"}. A total of 70 RA patients were enrolled, 4 were males and 66 females, with an age mean of 48±13 years and disease duration of 7.5 years, the clinical activity according to the DAS28 score was 5.1±1.6. A total of 74 CS were selected, 24 were male and 50 females, with a mean age of 37±12 years. Upon comparing the two groups, there was no statistically significant difference in height and BMI *(p*\>0.05, data not shown), and there was a significant difference in age, weight, inflammation markers (CRP and ESR) and RF (*p*\<0.05, data not shown).

Genotypes and allele frequencies of the *LEPR* Q223R polymorphism are shown in [Table 2](#table002){ref-type="table"} and they were in Hardy-Weinberg equilibrium (χ^2^ 0.08, *p*=0.77). When we evaluated the genotypes, no causal or statistical association was found between the RA patients and the control subjects.

Serum leptin levels were elevated in patients with RA as compared to CS (12.4 (1.7-48.5) ng/mL *vs* 9.4 (1.4-29.9) ng/mL, *p*=0.03) ([Figure 1](#fig001){ref-type="fig"}). When the serum leptin levels were stratified by genotype in RA patients group, the carriers of the AA genotype had a median of 13.4 (1.8-45.6) ng/mL, while carriers of the AG and GG genotypes had a median of 11.8 (1.6-52.5) ng/mL and 9.9 (2.4-52.5) ng/mL, respectively ([Figure 2A](#fig002){ref-type="fig"}). In the CS group, carriers of the AA genotype had a leptin median of 6.34 (0.7-23.5) ng/mL, while the carriers of the AG and GG genotypes had a median of 10.1 (1.5-31) ng/mL and 11.7 (1.6-36.1) ng/mL, respectively ([Figure 2B](#fig002){ref-type="fig"}).

In both groups, the mean differences were not statistically significant.

In RA patients, serum leptin levels correlated strongly with weight, height, and BMI. No correlation was found between leptin levels and RF, CRP, ESR, disease duration and DAS28 index ([Table 3](#table003){ref-type="table"}).

DISCUSSION {#sec1-4}
==========

Several studies suggest the importance of the adipose tissue as a hormone producer. These hormones are called "adipokines" which play an important role in immunity and inflammation. One of these hormones is leptin and emerging evidence indicates that this hormone acts as a proinflammatory cytokine in immune responses such as systemic lupus erythematosus, multiple sclerosis, psoriasis and RA ([@ref26]). Thus, the present study attempted to find an association between the Q223R leptin receptor gene polymorphism and leptin levels in patients with rheumatoid arthritis from Western Mexico. We found that RA patients had lower weight as compared to CS. These data are interesting because Chen Y et al., reported that in males with RA, the height is inversely associated with the severity of disease and disability, and this association is independent of other factors. In the case of females, it appears that there is an association of sex and a lower height with severe disease activity and disability ([@ref27]). The significantly lower weight in the RA patients is also consistent with a previous report, where weight, height, and BMI loss was significant in females with RA ([@ref27], [@ref28]). However, our results should be interpreted with caution, as most RA patients were women with very short stature as compared to the CS group. Additionally, it is notable that BMI value of patients and controls are the same.

Goldring SR et al., have argued that the loss in weight and height observed in RA patients could be explained by a generalized involvement of the bone tissue, that causes osteopenia and bone erosion ([@ref29]). Several studies propose that various factors such as proinflammatory cytokines, low mobility, and a poor nutrition can promote osteopenia ([@ref30]). This may be due to increased appetite-regulating adipokines such as leptin, as reported in certain inflammatory conditions, such as obesity or in this case in RA.

We found significantly elevated serum leptin levels in patients with RA as compared to the control subjects. These results are consistent with previous reports ([@ref4]). Although, the values that we report in this study are higher than the healthy subjects, they are considered low as compared to other populations ([@ref16], [@ref33]), this observation may be due to differences in age, sex and ethnical background ([@ref2], [@ref3], [@ref33], [@ref34]). Similarly to patients with obesity and insulin resistance, the observed increase in leptin levels may be explained in part by macrophage infiltration into the adipose tissue ([@ref35]) and not due to presence of the studied polymorphism. Further investigations are needed.

The frequencies of the allele G of the polymorphism Q223R *LEPR* gene reported in our study (0.42) are similar to those reported for Caucasians (0.41 to 0.58), and lower than that in Asians (0.81) ([@ref38]). Additionally, it needs to be noted that there is a marked difference in the frequency of this allele within the Mexican population ranging between 0.33-0.39 and 0.49 for Central Mexico ([@ref39],[@ref40]) and Western Mexico ([@ref25]), respectively, probably explained by the increased inter-racial mixing within the population ([@ref38], [@ref41]).

In the present study, we did not find an association between LEPR Q223R polymorphisms and serum leptin levels. These results are similar to those reported by others, where no significant differences were found in leptin levels with genotypes in healthy subjects and subjects with metabolic abnormalities ([@ref20], [@ref21], [@ref33]). Even *in vitro* experiments have shown that the presence of this polymorphism does not affect the signaling pathway of its receptor ([@ref42]).

In both groups, serum leptin levels had a strong correlation with BMI and weight, and are consistent with previous reports, which reported positive correlation between leptin levels and body composition variables in CS ([@ref43]) and RA patients ([@ref46]). On the other hand, in RA patients, no correlation was found between leptin levels and ESR, RF, CRP, disease duration and disease activity (DAS28). Some studies ([@ref10], [@ref49]) support our findings, while others have reported positive correlation between serum leptin with inflammatory markers ([@ref5], [@ref9]). This discrepancy could be explained by the differences in sample size, study design, and ethnic background.

CONCLUSION {#sec1-5}
==========

Our findings suggest that in patients with RA, there is no association between the *LEPR* Q223R polymorphism and RA, despite high serum leptin levels. The elevated leptin levels may explain the low weight observed in RA patients as compared to the control subjects. Furthermore, in our study the serum leptin levels did not correlate with the studied inflammatory markers, and disease severity and duration.

![Serum leptin levels in RA patients and CS\
Statistical analysis was performed using Mann-Whitney U test.](ejifcc-29-026-g001){#fig001}

![Comparison of circulating serum leptin levels according to *LEPR* Q223R genotype in RA patients (A) and CS (B)\
Statistical analysis was performed using Mann-Whitney U test.](ejifcc-29-026-g002){#fig002}

###### 

Clinical characteristics of the study groups

  Variables                                                         RA (n= 70)         CS (n=74)
  ----------------------------------------------------------------- ------------------ ---------------
  Age (years) ^[c](#tfn003){ref-type="table-fn"}^                   48 ± 13            37 ± 12
  Sex (male/female) ^[b](#tfn002){ref-type="table-fn"}^             4 /66              24/50
  Weight (kg) ^[a](#tfn001){ref-type="table-fn"}^                   60.2 (41.1-90.3)   67.35 (51-94)
  Height (m) ^[c](#tfn003){ref-type="table-fn"}^                    1.55 ± 0.1         1.64 ± 0.1
  BMI (kg/m^2^) ^[c](#tfn003){ref-type="table-fn"}^                 25.8 ± 5.1         25.9 ± 4.5
  **Disease status**                                                                   
  Duration of disease (years) ^[a](#tfn001){ref-type="table-fn"}^   7.5 (0.5-30)       
  DAS28 ^[c](#tfn003){ref-type="table-fn"}^                         5.1 ± 1.6          
  **Clinical assessment**                                                              
  Leukocytes (X10^9^/L) ^[c](#tfn003){ref-type="table-fn"}^         6.2 ± 1.8          6.4 ± 1.6
  CRP (mg/dL) ^[a](#tfn001){ref-type="table-fn"}^                   2.3 (0.3-40.8)     0.2 (0.1-0.9)
  ESR (mm/h) ^[c](#tfn003){ref-type="table-fn"}^                    37 ± 14            18.9 ± 11.7
  Rheumatoid factor (UI/mL) ^[a](#tfn001){ref-type="table-fn"}^     258.5 (20-3426)    20 (20-21.4)

^a^ Data provided in median (p5-p95)

^b^ Data provided in n

^c^ Data provided in mean ± SD

RA: rheumatoid arthritis; CS: control subject; ESR: erythrocyte sedimentation Rate; CRP: C reactive protein;

DAS-28: disease activity score 28. Normal distribution was determined using Kolmogorov-Smirnov test.

###### 

Genotypic distribution and allelic frequencies of Q223R polymorphism

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP                      Genotype                                   RA (n=70) % (n)   CS (n = 74)\   *p value^[a](#tfn004){ref-type="table-fn"}^*   OR (95% CI); *p*[§](#tfn006){ref-type="table-fn"}
                                                                                        % (n)                                                         
  ------------------------ ------------------------------------------ ----------------- -------------- ---------------------------------------------- ---------------------------------------------------
  ***668 A\>G (Q223R)***                                                                                                                              

  Codominant               AA^[b](#tfn005){ref-type="table-fn"}^      34.3(24)          33.8(25)       0.43                                           1.0

  AG                       54.3(38)                                   47.3(35)                         1.1 (0.54-2.33); 0.73                          

  GG                       11.4(8)                                    18.9(14)                         0.6 (0.21-1.67); 0.32                          

  Dominant                 AA^[b](#tfn005){ref-type="table-fn"}^      34.3(24)          33.8(25)       0.94                                           1.0

  AG+GG                    65.7(46)                                   66.2(49)                         0.9 (0.49-1.94); 0.94                          

  Recessive                AA+AG^[b](#tfn005){ref-type="table-fn"}^   88.6(62)          81.1(60)       0.21                                           1.0

  GG                       11.4(8)                                    18.9(14)                         0.5 (0.21-1.41); 0.21                          

  Allele                   A^[b](#tfn005){ref-type="table-fn"}^       61.4(86)          57.4(85)       0.49                                           1

  G                        38.6(54)                                   42.6(63)                         0.8 (0.52-1.35); 0.49                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Percentages were obtained by count direct.

RA: rheumatoid arthritis; CS: control subject; OR: odds ratio; 95% CI, 95% confidence interval;

^a^p value was calculated by χ^2^ test

^b^ Reference category

^§^p value was calculated by logistic regression.

###### 

Correlation between serum leptin levels and clinical characteristics of AR patients

                                                                Leptin levels   
  ------------------------------------------------------------- --------------- ---------
  Age (years)[\*](#tfn007){ref-type="table-fn"}                 0.172           0.154
  Height (kg)[\*](#tfn007){ref-type="table-fn"}                 0.534           \<0.001
  Weight (m)[\*](#tfn007){ref-type="table-fn"}                  -0.236          0.050
  BMI (Kg/m^2^)[\*](#tfn007){ref-type="table-fn"}               0.702           \<0.001
  ESR (mm/h)[\*\*](#tfn007){ref-type="table-fn"}                0.072           0.154
  CRP (mg/dL) [\*\*](#tfn007){ref-type="table-fn"}              0.121           0.317
  RF (UI/mL) [\*\*](#tfn007){ref-type="table-fn"}               0.018           0.880
  DAS28[\*](#tfn007){ref-type="table-fn"}                       -0.135          0.266
  Disease evolution (years)[\*](#tfn007){ref-type="table-fn"}   -0.018          0.881

Evaluated with Pearson\* or Spearman\*\* correlation.

RF: rheumatoid factor; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.
